 | Mild Cognitive Impairment and Diabetes Rosebud Roberts, M.D., a Mayo Clinic epidemiologist, discusses the results of her study. For more information, visit the Mayo Clinic News Blog at http://newsblog.mayoclinic.org/2008/08/11/mild-cognitive-impairment-associated-with-diabetes-duration-severity/ |
 | Empowered Health News | Blood Pressure Cognitive Impairment http://www.empowereddoctor.com/story_1359.html Approximately 50 million people in the U.S. suffer from hypertension, and what is most concerning is that nearly 15 million people are undiagnosed. The latest issue of Archives of Neurology has revealed that high blood pressure is associated with an increased risk of mild cognitive impairment-a condition that affects thinking and learning. Nearly 10 of every 1,000 elderly individuals without dementia develop mild cognitive impairment yearly. Of those, 10 percent to 12 percent progress to Alzheimer's disease each year, compared with 1 percent to 2 percent of the general population. During the study, Researchers followed over 900 Medicare recipients age 65 and over without mild cognitive impairment beginning in 1992 through 1994. Participants underwent an initial interview and physical, in addition to tests of cognitive function. They then were examined again every 18 months for an average of 4.7 years. Story is produced and provided by Empowered Medical Media, LLC Visit http://www.EmpoweredDoctor.com to see the full story And if you are looking for a doctor check out our local doctor directory at: http://www.empowereddoctor.com/directory_doctor.php |
 | MDTV: Parkinson's Disease Dementia "Parkinson's Disease Dementia" featuring Neurologist, Dr. Dee Silver, discusses how Parkinson's patients are 4 to 6 times more likely to develop some cognitive impairment. Up to 1 million people in the US are affected by IPD. After patients have had the disease 8 to 10 years, they have about an 80% chance of developing cognitive impairment. Dr. Silver talks about a new drug (Excelon) that is shown to hold off these impairments. Series: "MDTV (Medical Doctor Television) " [12/2007] [Health and Medicine] [Show ID: 13686] |
 | MDTV: Memory Loss II Neurologist, Dr. Dee Silver continues the discussion on causes and treatment of neurodegenerative diseases including Lewy Body Disease, Frontal Temporal Dementia and Vascular Dementia. Details of Mild Cognitive Impairment (MCI) are also covered. Treatments such as ACEI (Acetylcholinesterase Inhibitors) and GA Glutamate Antagonists are discussed. Series: "MDTV (Medical Doctor Television) " [4/2008] [Health and Medicine] [Show ID: 14227] |
 | Mayo Clinic MCI Study A new Mayo Clinic study found that the number of new cases of mild cognitive impairment is approximately 5 percent per year. This is higher than the anticipated 1 or 2 percent incidence rate and highlights the urgency for developing new and better therapies for Alzheimer's disease. Mild cognitive impairment (MCI) is a transitional state between normal aging and the earliest features of Alzheimer's disease. "If we extrapolate these findings to the baby boomers, who are aging into the period of risk, we're talking about a significant number of individuals who may become cognitively impaired in the very near future," says Ronald Petersen, M.D., Ph.D., a Mayo Clinic neurologist and director of the Mayo Clinic Alzheimer's Disease Research Center. "Consequently, if we don't find a cure or treatment to delay the onset of Alzheimer's disease, we're going to be overwhelmed by the burden of these individuals on the health care system." As part of the Mayo Clinic Study of Aging, nearly 2,000 healthy individuals aged 70 to 89 years from Olmsted County, Minn., have been followed over time to detect the earliest point of cognitive impairment. These individuals developed MCI at a rate of about 5.3 percent per year. The rate was even higher (7.2 percent) for 80-89 year olds. Dr. Petersen will be presenting this study at the Alzheimer's Association International Conference on Alzheimer's Disease in Chicago on July 28, 2008. Dr. Petersen provides an overview of the study, it's findings, how Mayo Clinic is trying to address the problem. |
 | Mayo Clinic MCI Study of MCI Rates (2) A new Mayo Clinic study found that the number of new cases of mild cognitive impairment is approximately 5 percent per year. This is higher than the anticipated 1 or 2 percent incidence rate and highlights the urgency for developing new and better therapies for Alzheimer's disease. Mild cognitive impairment (MCI) is a transitional state between normal aging and the earliest features of Alzheimer's disease. "If we extrapolate these findings to the baby boomers, who are aging into the period of risk, we're talking about a significant number of individuals who may become cognitively impaired in the very near future," says Ronald Petersen, M.D., Ph.D., a Mayo Clinic neurologist and director of the Mayo Clinic Alzheimer's Disease Research Center. "Consequently, if we don't find a cure or treatment to delay the onset of Alzheimer's disease, we're going to be overwhelmed by the burden of these individuals on the health care system." Dr. Petersen discusses the study findings. |
 | Mayo Clinic Study of MCI Rates (1) A new Mayo Clinic study found that the number of new cases of mild cognitive impairment is approximately 5 percent per year. This is higher than the anticipated 1 or 2 percent incidence rate and highlights the urgency for developing new and better therapies for Alzheimer's disease. Mild cognitive impairment (MCI) is a transitional state between normal aging and the earliest features of Alzheimer's disease. "If we extrapolate these findings to the baby boomers, who are aging into the period of risk, we're talking about a significant number of individuals who may become cognitively impaired in the very near future," says Ronald Petersen, M.D., Ph.D., a Mayo Clinic neurologist and director of the Mayo Clinic Alzheimer's Disease Research Center. "Consequently, if we don't find a cure or treatment to delay the onset of Alzheimer's disease, we're going to be overwhelmed by the burden of these individuals on the health care system." Dr. Petersen provides an overview of the study. |
 | Mayo Clinic MCI Study of MCI Rates (3) A new Mayo Clinic study found that the number of new cases of mild cognitive impairment is approximately 5 percent per year. This is higher than the anticipated 1 or 2 percent incidence rate and highlights the urgency for developing new and better therapies for Alzheimer's disease. Mild cognitive impairment (MCI) is a transitional state between normal aging and the earliest features of Alzheimer's disease. "If we extrapolate these findings to the baby boomers, who are aging into the period of risk, we're talking about a significant number of individuals who may become cognitively impaired in the very near future," says Ronald Petersen, M.D., Ph.D., a Mayo Clinic neurologist and director of the Mayo Clinic Alzheimer's Disease Research Center. "Consequently, if we don't find a cure or treatment to delay the onset of Alzheimer's disease, we're going to be overwhelmed by the burden of these individuals on the health care system." Dr. Petersen discusses what Mayo Clinic is doing to address these concerns. |
 | What If... Brain Injury Rehabilitation What if you woke up one day and you didn't know who or where you were? Or seemed to have half the body you had before? And what if you couldn't even tell people about it? Informational video about brain injury. Univ. Texas Medical Branch School of Allied Health Sciences http://sahs.utmb.edu Transitional Learning Center http://www.tlcrehab.org |
 | Study hopes to provide answers to chemo fog It's a life-saving therapy, but scientists are learning that a persistent problem surfaces in many chemotherapy patients. The problem is chemo brain or chemo fog. Researchers say as many as 30 percent of chemotherapy patients suffer from chemo fog causing mild to moderate cognitive brain impairment. With the help of funding from well-known cancer survivor and athlete Lance Armstrong, researchers at Vanderbilt Medical Center in Nashville, Tennessee, have started the first-ever study hoping to clear some chemo fog. Barb Cramer has the story. |
 | Live With Rett Syndrome Rett syndrome is a neurodevelopmental disorder that is classified as a pervasive developmental disorder by the DSM-IV. Many argue that this is a misclassification just as it would be to include such disorders as fragile X syndrome, tuberous sclerosis, or Down syndrome where one can see autistic features. The symptoms of this disorder are most easily confused with those of Angelman syndrome and autism. The clinical features include a deceleration of the rate of head growth (including microcephaly in some) and small hands and feet. Stereotypic, repetitive hand movements such as mouthing or wringing are also noted. Symptoms of the disorder include cognitive impairment and problems with socialization, the latter during the regression period. Socialization typically improves by the time they enter school. Girls with Rett syndrome are very prone to gastrointestinal disorders and up to 80% have seizures. They typically have no verbal skills, and about 50% of females are not ambulatory. Scoliosis, growth failure, and constipation are very common and can be problematic. |
 | FDA Approves First Drug to Help Patients with Parkinson's Di August 2006 (Medialink) -- Statistics: According to the National Parkinson Foundation (NPF), dementia is one of the complications most feared by Parkinson's disease patients and caregivers. Of the 1.5 million Americans living with the disease, an estimated 40% develop dementia. Story: The U.S. Food and Drug Administration (FDA) has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia, making it the first approved medication available for the treatment of this condition. The risk of developing dementia is approximately four to six times higher among Parkinson's patients than among elderly people without the disease. The primary symptoms of Parkinson's disease dementia include cognitive impairment and neuro-psychiatric symptoms (e.g., depression, hallucinations, anxiety and apathy). These symptoms impact the patient's quality of life, course of the disease and caregiver distress. While this drug is now being used to treat Parkinson's patients with dementia, for years it has been used to in the treatment of Alzheimer's disease. Produced for Novartis Pharmaceuticals Corporation |
العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
Español
